Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo

Shou Hung Tang, Hsu Shan Huang, Hong Ui Wu, Yi Ta Tsai, Mei Jen Chuang, Cheng Ping Yu, Shih Ming Huang, Guang Huan Sun, Sun Yran Chang, Pei Wen Hsiao, Dah Shyong Yu, Tai Lung Cha

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The polycomb group gene, EZH2, is highly expressed in advanced bladder cancer. Here we demonstrated that down-regulation of EZH2 in tumor tissues after neoadjuvant chemotherapy correlated with good therapeutic response in advanced bladder cancer. We next developed a small molecule, NSC745885, derived from natural anthraquinone emodin, which down-regulated EZH2 via proteasome-mediated degradation. NSC745885 showed potent selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 treatment overcame multiple-drug resistance and inhibited growth of resistant cancer cells. Over-expression of EZH2 in cancer cells attenuated effects of NSC745885, suggesting that down-regulation of EZH2 was responsible for growth inhibition of NSC745885. NSC745885 also suppressed tumor growth and down-regulated EZH2 in vivo. These results indicate that NSC7455889 suppresses bladder cancer by targeting EZH2.

Original languageEnglish
Pages (from-to)10342-10355
Number of pages14
JournalOncotarget
Volume5
Issue number21
Publication statusPublished - 2014

Fingerprint

Urinary Bladder Neoplasms
Down-Regulation
Neoplasms
Growth
Emodin
Anthraquinones
Multiple Drug Resistance
Proteasome Endopeptidase Complex
anthra(2,1-c)(1,2,5)thiadiazole-6,11-dione
In Vitro Techniques
Drug Therapy
Cell Line
Therapeutics
Genes

Keywords

  • Ezh2
  • G2/M cell-cycle arrest
  • Nsc745885
  • Proteasome degradation

ASJC Scopus subject areas

  • Oncology

Cite this

Tang, S. H., Huang, H. S., Wu, H. U., Tsai, Y. T., Chuang, M. J., Yu, C. P., ... Cha, T. L. (2014). Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo. Oncotarget, 5(21), 10342-10355.

Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo. / Tang, Shou Hung; Huang, Hsu Shan; Wu, Hong Ui; Tsai, Yi Ta; Chuang, Mei Jen; Yu, Cheng Ping; Huang, Shih Ming; Sun, Guang Huan; Chang, Sun Yran; Hsiao, Pei Wen; Yu, Dah Shyong; Cha, Tai Lung.

In: Oncotarget, Vol. 5, No. 21, 2014, p. 10342-10355.

Research output: Contribution to journalArticle

Tang, SH, Huang, HS, Wu, HU, Tsai, YT, Chuang, MJ, Yu, CP, Huang, SM, Sun, GH, Chang, SY, Hsiao, PW, Yu, DS & Cha, TL 2014, 'Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo', Oncotarget, vol. 5, no. 21, pp. 10342-10355.
Tang SH, Huang HS, Wu HU, Tsai YT, Chuang MJ, Yu CP et al. Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo. Oncotarget. 2014;5(21):10342-10355.
Tang, Shou Hung ; Huang, Hsu Shan ; Wu, Hong Ui ; Tsai, Yi Ta ; Chuang, Mei Jen ; Yu, Cheng Ping ; Huang, Shih Ming ; Sun, Guang Huan ; Chang, Sun Yran ; Hsiao, Pei Wen ; Yu, Dah Shyong ; Cha, Tai Lung. / Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo. In: Oncotarget. 2014 ; Vol. 5, No. 21. pp. 10342-10355.
@article{3142cfa5499c4848adc59714c29fca23,
title = "Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo",
abstract = "The polycomb group gene, EZH2, is highly expressed in advanced bladder cancer. Here we demonstrated that down-regulation of EZH2 in tumor tissues after neoadjuvant chemotherapy correlated with good therapeutic response in advanced bladder cancer. We next developed a small molecule, NSC745885, derived from natural anthraquinone emodin, which down-regulated EZH2 via proteasome-mediated degradation. NSC745885 showed potent selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 treatment overcame multiple-drug resistance and inhibited growth of resistant cancer cells. Over-expression of EZH2 in cancer cells attenuated effects of NSC745885, suggesting that down-regulation of EZH2 was responsible for growth inhibition of NSC745885. NSC745885 also suppressed tumor growth and down-regulated EZH2 in vivo. These results indicate that NSC7455889 suppresses bladder cancer by targeting EZH2.",
keywords = "Ezh2, G2/M cell-cycle arrest, Nsc745885, Proteasome degradation",
author = "Tang, {Shou Hung} and Huang, {Hsu Shan} and Wu, {Hong Ui} and Tsai, {Yi Ta} and Chuang, {Mei Jen} and Yu, {Cheng Ping} and Huang, {Shih Ming} and Sun, {Guang Huan} and Chang, {Sun Yran} and Hsiao, {Pei Wen} and Yu, {Dah Shyong} and Cha, {Tai Lung}",
year = "2014",
language = "English",
volume = "5",
pages = "10342--10355",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "21",

}

TY - JOUR

T1 - Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo

AU - Tang, Shou Hung

AU - Huang, Hsu Shan

AU - Wu, Hong Ui

AU - Tsai, Yi Ta

AU - Chuang, Mei Jen

AU - Yu, Cheng Ping

AU - Huang, Shih Ming

AU - Sun, Guang Huan

AU - Chang, Sun Yran

AU - Hsiao, Pei Wen

AU - Yu, Dah Shyong

AU - Cha, Tai Lung

PY - 2014

Y1 - 2014

N2 - The polycomb group gene, EZH2, is highly expressed in advanced bladder cancer. Here we demonstrated that down-regulation of EZH2 in tumor tissues after neoadjuvant chemotherapy correlated with good therapeutic response in advanced bladder cancer. We next developed a small molecule, NSC745885, derived from natural anthraquinone emodin, which down-regulated EZH2 via proteasome-mediated degradation. NSC745885 showed potent selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 treatment overcame multiple-drug resistance and inhibited growth of resistant cancer cells. Over-expression of EZH2 in cancer cells attenuated effects of NSC745885, suggesting that down-regulation of EZH2 was responsible for growth inhibition of NSC745885. NSC745885 also suppressed tumor growth and down-regulated EZH2 in vivo. These results indicate that NSC7455889 suppresses bladder cancer by targeting EZH2.

AB - The polycomb group gene, EZH2, is highly expressed in advanced bladder cancer. Here we demonstrated that down-regulation of EZH2 in tumor tissues after neoadjuvant chemotherapy correlated with good therapeutic response in advanced bladder cancer. We next developed a small molecule, NSC745885, derived from natural anthraquinone emodin, which down-regulated EZH2 via proteasome-mediated degradation. NSC745885 showed potent selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 treatment overcame multiple-drug resistance and inhibited growth of resistant cancer cells. Over-expression of EZH2 in cancer cells attenuated effects of NSC745885, suggesting that down-regulation of EZH2 was responsible for growth inhibition of NSC745885. NSC745885 also suppressed tumor growth and down-regulated EZH2 in vivo. These results indicate that NSC7455889 suppresses bladder cancer by targeting EZH2.

KW - Ezh2

KW - G2/M cell-cycle arrest

KW - Nsc745885

KW - Proteasome degradation

UR - http://www.scopus.com/inward/record.url?scp=84916885240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916885240&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 10342

EP - 10355

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 21

ER -